Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Accounts Payables (2021 - 2024)

Historic Accounts Payables for Pharmaceuticals (CASI) over the last 4 years, with Q4 2024 value amounting to $15.3 million.

  • Pharmaceuticals' Accounts Payables rose 2486.98% to $15.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $15.3 million, marking a year-over-year increase of 2486.98%. This contributed to the annual value of $15.3 million for FY2024, which is 2486.98% up from last year.
  • Per Pharmaceuticals' latest filing, its Accounts Payables stood at $15.3 million for Q4 2024, which was up 2486.98% from $12.3 million recorded in Q4 2023.
  • Pharmaceuticals' 5-year Accounts Payables high stood at $15.3 million for Q4 2024, and its period low was $11.0 million during Q4 2021.
  • In the last 4 years, Pharmaceuticals' Accounts Payables had a median value of $12.1 million in 2022 and averaged $12.6 million.
  • As far as peak fluctuations go, Pharmaceuticals' Accounts Payables skyrocketed by 399.46% in 2023, and later soared by 2486.98% in 2024.
  • Pharmaceuticals' Accounts Payables (Quarter) stood at $11.0 million in 2021, then increased by 7.78% to $11.8 million in 2022, then grew by 3.99% to $12.3 million in 2023, then grew by 24.87% to $15.3 million in 2024.
  • Its Accounts Payables stands at $15.3 million for Q4 2024, versus $12.3 million for Q4 2023 and $11.8 million for Q4 2022.